AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2888937
Drug: Antidepressants (imipramine)
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (imipramine)
Trial: 28434056
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention targeting maternal alcohol use, malnutrition, and HIV, specific dosage and duration not available
Trial: 22773391
Drug: Sequential portal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential portal and arterial revascularization (SPAr)
Trial: 17059015
Drug: Four-step therapeutics
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-step therapeutics of Traditional Chinese Medicine (TCM)
Trial: 17059015
Drug: 100mg Lamivudine
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg Lamivudine orally daily for two years (Control)
Trial: 10908991
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with Meniett apparatus
Trial: 8113660
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg of prostaglandin E2 in 3 ml of gel intracervically
Trial: 8113660
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg prostaglandin E2 tablet intravaginally
Trial: 31618456
Drug: Reduced-dose plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose plerixafor (0.12 mg/kg) plus filgrastim (10 μg/kg/4 days)
Trial: 26572609
Drug: Protein-rich nutritional
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-rich nutritional supplementation (40g of protein and 600 kcal daily for six months) and bisphosphonates (once weekly for 12 months)
Trial: 26572609
Drug: Bisphosphonates alone
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonates alone (once weekly for 12 months)
Trial: 26572609
Drug: Calcium (1g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1g daily) and vitamin D3 (800 IU daily)
Trial: 23546559
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide (N2O) by inhalation
Trial: 23546559
Drug: Deep sedation
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep sedation (intravenous mixture of midazolam, remifentanil, and propofol)
Trial: 9722274
Drug: Control (water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (water solution)
Trial: 2730998
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (300 mg/kg body weight)
Trial: 2730998
Drug: Placebo (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (8 g sodium chloride)
Trial: 1101842
Drug: Very high
RxNorm normalized name: Very high density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very high dose fluphenazine (1,200 mg/day)
Trial: 1101842
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose fluphenazine
Trial: 31951771
Drug: HepB control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HepB control vaccine
Trial: 24697345
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment combined with bladder training (n = 440)
Trial: 24697345
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment alone (n = 405)
Trial: 29354930
Drug: Skin needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin needle embedding therapy
Trial: 18928105
Drug: Non-steroid anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid anti-inflammatory drugs
Trial: 12373475
Drug: Early surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early surfactant administration (Curosurf at a dose of 100 mg/kg as a single bolus via the endotracheal tube within 1 min after intubation)
Trial: 12373475
Drug: Delayed surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed surfactant administration (during HFOV only when defined criteria were reached)
Trial: 12373475
Drug: Delayed surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed surfactant administration
Trial: 7760659
Drug: Cortisporin Otic
RxNorm normalized name: Cortisporin Otic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisporin Otic Suspension (COS; 0.5 mL)
Trial: 2081608
Drug: Propranolol (80-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80-160 mg per day)
Trial: 2081608
Drug: Acebutolol (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (400-800 mg per day)
Trial: 29461121
Drug: Topical 3%
RxNorm normalized name: sulfur topical 3% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 3% tranexamic acid combined with 1064-nm QSNYL laser
Trial: 25123170
Drug: Three daily
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three daily servings of dairy products
Trial: 18688814
Drug: B. macrostemi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B. macrostemi plus baseline therapy
Trial: 18688814
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus baseline therapy
Trial: 16367880
Drug: Pioglitazone (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15, 30, and 45 mg)
Trial: 3559982
Drug: Morphine (7.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (7.5, 15, and 30 mg)
Trial: 3559982
Drug: Pentazocine (22.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (22.5, 45, and 90 mg)
Trial: 3559982
Drug: Ciramadol (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciramadol (30, 60, and 120 mg)
Trial: 22298568
Drug: Oral tocotrienols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tocotrienols (200 mg mixed tocotrienols, b.i.d.)
Trial: 22298568
Drug: Oral tocopherols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tocopherols (200 mg α‐tocopherol, b.i.d.)
Trial: 22834565
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) therapy
Trial: 18245019
Drug: Metabotropic glutamate
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metabotropic glutamate receptor agonists
Trial: 18245019
Drug: Dopamine receptor‐blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine receptor‐blocking drugs
Trial: 15914552
Drug: R-CHOP (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP (375 mg/m2 rituximab with each chemotherapy cycle, n = 99)
Trial: 15914552
Drug: CHOP (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP (no immunotherapy, n = 50)
Trial: 7703929
Drug: Ampho‐B/G (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampho‐B/G (1 mg/kg)
Trial: 7703929
Drug: Ampho‐B/Lipid (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampho‐B/Lipid (1 mg/kg)
Trial: 7703929
Drug: AmBisome (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome (3 mg/kg)
Trial: 495529
Drug: Hypnotic subjects
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic subjects
Trial: 29257754
Drug: rs4693075 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rs4693075 in patients suffering SAMS (CC=36.8%, CG=48.2%, GG=15.0%)
Trial: 14766438
Drug: Buspirone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone treatment
Trial: 20562170
Drug: Estrogen pre-treatment
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen pre-treatment
Trial: 20562170
Drug: Buspirone after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone after estrogen pre-treatment
Trial: 19393480
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anti-dyslipidemic therapy)
Trial: 11219208
Drug: Intracoronary radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary radiation therapy
Trial: 11219208
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (angioplasty and stenting)
Trial: 15881488
Drug: Sulfonylurea plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea plus metformin
Trial: 4558903
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of Delta(9)‐tetrahydrocannabinol and 11‐OH‐Delta(9)‐tetrahydrocannabinol
Trial: 23663534
Drug: Mindfulness-based meditation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based meditation intervention (8 weekly sessions, 90 min each)
Trial: 21859484
Drug: Nebulized beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized beclomethasone dipropionate (BDP) 400 μg b.i.d. plus nebulized salbutamol 2500 μg prn
Trial: 21859484
Drug: Nebulized placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized placebo plus nebulized salbutamol 2500 μg prn
Trial: 17317044
Drug: Early home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early home-based intervention with monthly specific home visits between the infant ages of 5 and 9 months
Trial: 11929404
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once a day
Trial: 11929404
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg twice a day
Trial: 2916514
Drug: Theophylline (Theo-Dur
RxNorm normalized name: THEOPHYLLINE (THEO-DUR) 300MG SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (Theo-Dur tablets, 14 to 16 mg/kg per day or their usual dose, whichever was higher)
Trial: 768909
Drug: acebutolol 500
RxNorm normalized name: acebutolol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acebutolol 500 mg
Trial: 768909
Drug: bendrofluazide 5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bendrofluazide 5-15 mg
Trial: 29127558
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (4 mg)
Trial: 28449690
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg iron as NaFeEDTA
Trial: 28449690
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg iron as encapsulated ferrous fumarate
Trial: 20021666
Drug: Tetrabenazine (TBZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrabenazine (TBZ), maximum dosage of 200 mg/day, titrated to the best individual dose over 80 weeks.
Trial: 15152555
Drug: Alfetin (biological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfetin (biological preparation)
Trial: 30047357
Drug: Exposure in
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure in vivo (EXP), a cognitive-behavioral treatment targeting pain-related fear
Trial: 30047357
Drug: Pain-contingent physical
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain-contingent physical therapy (PPT)
Trial: 27146814
Drug: Pantoprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (40 mg ID for 2 days)
Trial: 27146814
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg) alone
Trial: 16260822
Drug: Internet-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioral therapy with minimal therapist contact plus participation in a discussion group
Trial: 12137110
Drug: Hydrostatic anti-G
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrostatic anti-G suit (Libelle; L)
Trial: 12137110
Drug: Pneumatic anti-G
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumatic anti-G ensemble (AGE-39) with full anti-G straining maneuvers (FM)
Trial: 12137110
Drug: Pneumatic anti-G
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumatic anti-G ensemble (AGE-39) with reduced anti-G straining maneuvers (RM)
Trial: 10594422
Drug: rocuronium (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium (20 mg)
Trial: 10594422
Drug: vecuronium (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vecuronium (4 mg)
Trial: 12812862
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (synthetic estrogens)
Trial: 12812862
Drug: Oral Contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptive (OC) use
Trial: 45463
Drug: Lergotrile mesylate
RxNorm normalized name: Lergotrile mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lergotrile mesylate (2 mg oral)
Trial: 25568388
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (posterior or anterior arthrodesis)
Trial: 25568388
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (body cast or orthosis)
Trial: 17073812
Drug: High-dose human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose human ALB (albumin) therapy
Trial: 8336224
Drug: Midazolam (.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (.35 mg/kg)
Trial: 8336224
Drug: Diazepam (.70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (.70 mg/kg)
Trial: 3534348
Drug: Dexamethasone (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (IV 16 mg 1/2 hr before and 8 mg at 1 1/2, 3 1/2, and 5 1/2 hr after cisplatin)
Trial: 3534348
Drug: Metoclopramide (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (IV 2 mg/kg 1/2 hr before and 1 1/2, 3 1/2, and 5 1/2 hr after cisplatin)
Trial: 3534348
Drug: Overall response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Overall response to antiemetic agents
Trial: 29590698
Drug: Standardised cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised cooling and compression therapy with the Cryo/Cuff™‐system (3 × 10 min twice daily)
Trial: 29590698
Drug: Conventional cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cooling therapy
Trial: 26928670
Drug: Celecoxib 800
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 800 mg/day
Trial: 24572997
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg intravenously over 2 hours)
Trial: 24572997
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline 5 mL/kg intravenously)
Trial: 19884368
Drug: Nemonoxacin 125
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 125 mg
Trial: 25092690
Drug: Nemonoxacin 250
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 250 mg
Trial: 25092690
Drug: Nemonoxacin 500
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 500 mg
Trial: 25092690
Drug: Nemonoxacin 750
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 750 mg
Trial: 22650326
Drug: Nemonoxacin 500
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 500 mg (multiple doses)
Trial: 22650326
Drug: Nemonoxacin 500
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 500 mg (fed conditions)
Trial: 20306554
Drug: Raltegravir 200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 200, 400, or 600 mg b.i.d. plus optimized background therapy
Trial: 20306554
Drug: Placebo b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo b.i.d. plus optimized background therapy
Trial: 18310400
Drug: Carefully selected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carefully selected pharmacological therapy
Trial: 12588019
Drug: 2TU PPD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2TU PPD prepared by the Guindy laboratory (Dilution-G)
Trial: 12588019
Drug: 1TU and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1TU and 2TU Dilution-G
Trial: 10583708
Drug: Intravenous Mg
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Mg load with 0.1 mmol Mg-aspartate hydrochloride per kilogram bodyweight for 1 hour.
Trial: 10583708
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group receiving no Mg medication.
Trial: 10583708
Drug: Baseline Mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline Mg values measured by atomic absorption spectroscopy (AAS) in serum and urine.
Trial: 10583708
Drug: Femur Mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femur Mg concentration measured by AAS.
Trial: 10583708
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of femur Mg concentration and %Ret.
Trial: 6198313
Drug: Radiation followed
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation followed by chemotherapy (sequential)
Trial: 6198313
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with temporary interruption for radiation (sandwich)
Trial: 29504498
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled glucocorticoids (fluticasone at a dose of 220 μg per inhalation, two inhalations twice daily) for 7 days at early signs of loss of asthma control.
Trial: 29504498
Drug: Low-dose inhaled
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose inhaled glucocorticoids (fluticasone propionate at a dose of 44 μg per inhalation, two inhalations twice daily) continued.
Trial: 26474541
Drug: Implant sites
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant sites with <2 mm of keratinized mucosa (Narrow Group)
Trial: 26474541
Drug: Implant sites
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant sites with ≥2 mm of keratinized mucosa (Wide Group)
Trial: 15139955
Drug: Topical fluoride
RxNorm normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluoride varnish (0.1 mg, Duraphat) for 6 h
Trial: 9589293
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g mesalamine enema
Trial: 9589293
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g mesalamine enema
Trial: 9589293
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g mesalamine enema
Trial: 2972628
Drug: Short interval
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short interval regimen (10 micrograms of Merck Sharp & Dohme recombinant HB vaccine at 0, 2, and 6 weeks)
Trial: 23146293
Drug: ranolazine, 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranolazine, 375 mg bid for 3 weeks (group 1)
Trial: 23146293
Drug: ranolazine, 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranolazine, 375 mg bid for 2 weeks, followed by placebo bid for 1 week (group 2)
Trial: 19364687
Drug: Cholecalciferol (vitamin
RxNorm normalized name: cholecalciferol (vitamin D3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (vitamin D3) 50,000 units weekly for 8 weeks
Trial: 19364687
Drug: Severely deficient
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severely deficient patients (25[OH]D <10 ng/mL) treated in an unblinded fashion
Trial: 11095487
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen (Premarin), 0.625 mg/day
Trial: 11095487
Drug: Droloxifene, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene, 60 mg/day
Trial: 11095487
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment for 4 weeks)
Trial: 9050018
Drug: Noradrenaline (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline (i.v. infusion at doses of 10-160 ng/kg/min)
Trial: 9050018
Drug: Noradrenaline (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline (i.v. infusion)